Sanofi, a global pharmaceutical organisation, has implemented Elsevier’s QUOSA literature management tools to automate adverse event monitoring. QUOSA powers the retrieval, storage, tagging and annotation of relevant case reports, allowing for the creation of a centralised repository of product-related scientific literature. This centralised repository supports Sanofi’s Pharmacovigilance team in drug safety and adverse event monitoring, ensuring patient safety and compliance with regulatory reporting requirements in all the markets in which it operates.
QUOSA’s pharmacovigilance solution features three elements that help companies meet their literature tracking objectives. First, Elsevier provides prompt customised professional services through its dedicated Life Sciences Integration Services team. Second, QUOSA can be used as either a desktop application or browser-based technology, facilitating secure and scalable information sharing across multiple regions. Third, QUOSA easily integrates with already existing literature resources like third-party publisher platforms, A&I databases like Embase, and document delivery vendors.
‘Pharmaceutical companies are continually challenged to ensure regulatory compliance is met. This is no easy task with limited resources, an ever-growing number of literature articles and an increasing portfolio of drugs to be tracked. Left untamed, this presents significant risks in compliance and crucially, in patient safety,’ said Michael Rai, general manager of QUOSA at Elsevier. ‘In response to our many conversations with information professionals, we have finely tuned QUOSA to complement current processes to provide a stable, efficient and scalable solution which continues to evolve with future needs. We look forward to working with Sanofi to manage this flow of information and support its Pharmacovigilance teams’ work.’
